Naonobu Sugiyama

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi et al. · Arthritis Research & Therapy · 2016 · 148 citations · Full text

Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)

Hisashi Yamanaka, Naonobu Sugiyama, Eisuke Inoue et al. · Modern Rheumatology · 2013 · 143 citations · Full text

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

Jeffrey R. Curtis, Kunihiro Yamaoka, Yi‐Hsing Chen et al. · Annals of the Rheumatic Diseases · 2022 · 139 citations · Full text

Membranous Glomerulonephritis Development with Th2-Type Immune Deviations in MRL/<i>lpr</i> Mice Deficient for IL-27 Receptor (WSX-1)

Sakiko Shimizu, Naonobu Sugiyama, Kohsuke Masutani et al. · The Journal of Immunology · 2005 · 108 citations · Full text

Protection against autoimmune nephritis in MyD88‐deficient MRL/lpr mice

Atsushi Sadanaga, Hitoshi Nakashima, Mitsuteru Akahoshi et al. · Arthritis & Rheumatism · 2007 · 108 citations